The Worldwide Cervical Cancer Diagnostic Market is Projected to reach USD 10.2 Billion by 2029, at a CAGR of 4.4%

Cervical Cancer Diagnostic Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global Cervical Cancer Diagnostic Market size is expected to reach $10.2 billion by 2029, rising at a market growth of 4.4% CAGR during the forecast period.

The HPV Test segment is showcasing a CAGR of 4.8% during (2023 - 2029). This is due to human papillomavirus (HPV) infection and the accessibility of home-based HPV test sample collection kits. Women over 30 are advised to undergo an HPV test to detect the infection. The diagnosis aids in detecting precancerous lesions caused by HPV, which may be surgically removed to prevent the progression of invasive cancers. In most cases, cervical cancer can be prevented by detecting and treating aberrant cell changes in the cervix years before the disease develops.

The 20 to 40 years segment acquired maximum revenue share in the Global Cervical Cancer Diagnostic Market by Age Group in 2022 thereby, achieving a market value of $7.6 billion by 2029. This is due to the high prevalence of cervical cancer in the 20-to-40-year-old population, as well as the increase in the number of patients seeking cervical cancer diagnosis at hospitals. Thus, in the future years, the segment share is likely to increase as this age group's women become increasingly aware about these tests to treat and diagnose cervical cancer.

The North America market dominated the Global Cervical Cancer Diagnostic Market by Region in 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $3.9 billion by 2029. The Europe market is experiencing a CAGR of 4% during (2023 - 2029). Additionally, The Asia Pacific market would showcase a CAGR of 5.2% during (2023 - 2029).

Full Report: https://www.kbvresearch.com/cervical-cancer-diagnostic-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Becton, Dickinson and Company, Carl Zeiss AG, CooperSurgical, Inc. (The Cooper Companies, Inc.), DYSIS Medical, Inc., F. Hoffmann-La Roche Ltd., Hologic, Inc., Qiagen N.V., Siemens Healthineers AG (Siemens AG) and Thermo Fisher Scientific, Inc.

Global Cervical Cancer Diagnostic Market Segmentation

By Type

• Pap Smear Tests
• Colposcopy Tests
• HPV Test
• Biopsy & ECC
• Others

By Age Group

• 20 to 40 years
• Above 40 years

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

• Abbott Laboratories
• Becton, Dickinson and Company
• Carl Zeiss AG
• CooperSurgical, Inc. (The Cooper Companies, Inc.)
• DYSIS Medical, Inc.
• F.Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Qiagen N.V.
• Siemens Healthineers AG (Siemens AG)
• Thermo Fisher Scientific, Inc.

Related Reports:

North America Cervical Cancer Diagnostic Market Size to 2029

• May-2023
• 88 Pages

LAMEA Cervical Cancer Diagnostic Market Size, Growth, 2029

• May-2023
• 96 Pages

Europe Cervical Cancer Diagnostic Market Size Report, 2029

• May-2023
• 96 Pages

Asia Pacific Cervical Cancer Diagnostic Market Size to 2029

• May-2023
• 97 Pages